Open AccessImpact of pre-existing drug resistance on risk of virological failure in South Africa
Author(s) -
Jonathan Z. Li,
Natalia Stella,
Manish Choudhary,
Aneela Javed,
Katherine Rodríguez,
Heather Ribaudo,
Mahomed-Yunus S. Moosa,
Jay Brijkumar,
Selvan Pillay,
Henry Sunpath,
Marc Noguera-Julián,
Roger Paredes,
Brent A. Johnson,
Alex Edwards,
Vincent C. Marconi,
Daniel R. Kuritzkes
Publication year - 2021
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkab062
Subject(s) - efavirenz , medicine , emtricitabine , drug resistance , population , cohort , proportional hazards model , drug , human immunodeficiency virus (hiv) , viral load , cohort study , antiretroviral therapy , virology , pharmacology , biology , genetics , environmental health
There is conflicting evidence on the impact of pre-existing HIV drug resistance mutations (DRMs) in patients infected with non-B subtype virus.